Antibiotics and Drug Resistance

Test yourself on Antibiotics and Drug Resistance with exam style questions, marked instantly.

Flashcards that come back just before you would forget them.

A revision plan that remembers what you know and shows what to do next.

See which topics you have nailed and which need another look.

Quiz yourself on Antibiotics and Drug ResistanceGet your flashcardsBuild my revision planTrack my progress

From Miracle Cure to Modern Crisis

In 1928, Alexander Fleming returned to his laboratory to find something extraordinary: a patch of mould had grown on a petri dish of bacteria — and the bacteria around it had died. This chance discovery led to penicillin, the first antibiotic, which went on to save millions of lives from infections that had previously been fatal. It felt like medicine had won.

But the victory was not permanent. Since antibiotics came into widespread use in the 1940s, bacteria have been fighting back through the relentless engine of natural selection. Today, MRSA infections are difficult to treat in hospitals, some strains of tuberculosis resist multiple drugs, and the World Health Organisation warns that antibiotic resistance is one of the greatest threats to global health. The story of antibiotics is both one of medicine's greatest triumphs and one of its most pressing ongoing challenges.

Key Facts About Antibiotics

  • Definition: Chemicals that kill bacteria (bactericidal) or stop their growth (bacteriostatic)
  • Target: Only work against bacterial infections, NOT viral infections
  • Sources: Originally from fungi and bacteria, now many are synthetic
  • Examples: Penicillin, amoxicillin, tetracycline, erythromycin
  • Broad-spectrum: Work against many types of bacteria
  • Narrow-spectrum: Target specific bacterial species

How Antibiotics Work: Mechanisms of Action

1. Cell Wall Disruption

Many antibiotics (like penicillin) target the bacterial cell wall by:

  • Preventing the formation of peptidoglycan, a key component of bacterial cell walls
  • Weakening the cell wall structure
  • Causing bacteria to burst due to osmotic pressure

2. Protein Synthesis Inhibition

Some antibiotics (like streptomycin) target bacterial ribosomes:

  • Bind to bacterial ribosomes (different from human ribosomes)
  • Prevent the production of essential proteins
  • Stop bacterial growth and reproduction

3. DNA Interference

Certain antibiotics disrupt bacterial DNA replication and repair, preventing cell division.

4. Membrane Disruption

Some antibiotics damage the bacterial cell membrane, causing cell contents to leak out.

🧪 Required Practical: Investigating Antibiotic Action

Disc Diffusion Method

Aim: To investigate the effectiveness of different antibiotics against bacterial growth

Method:

  1. Prepare sterile agar plates
  2. Spread bacterial culture evenly across the plate
  3. Place antibiotic discs on the surface
  4. Incubate at 25°C for 24-48 hours
  5. Measure zones of inhibition around each disc

Results Interpretation:

  • Large zone: Antibiotic is very effective
  • Small zone: Antibiotic has limited effectiveness
  • No zone: Bacteria are resistant to the antibiotic

Aseptic Techniques:

  • Work near a Bunsen burner flame for sterile updraft
  • Flame bottle necks before and after use
  • Use sterile equipment (autoclave sterilization)
  • Handle petri dish lids carefully - don't lift fully
  • Seal plates with tape after inoculation

How Antibiotic Resistance Develops

Painted illustration showing how antibiotic resistance evolves. Three Petri dishes in a row: dish 1 shows mostly teal-blue sensitive bacterial colonies plus one red-orange resistant mutant marked with a star (1 in millions). Dish 2 shows the antibiotic disc in the centre with most teal bacteria faded and crossed-out (dead), only the red R surviving. Dish 3 shows the dish filled with red-orange resistant colonies. Below on a painted parchment scroll: 4 numbered mark points (variation, selection pressure, reproduction, population shift). Bottom in red ink: 'Examiner trap — don't say bacteria become resistant; they ARE resistant by mutation, selection just favours them.'

Figure: Natural selection in 3 stages — variation, selection, then a fully resistant population.

The Process of Natural Selection:

  1. Genetic Variation: Random mutations in bacterial DNA create variation in populations
  2. Selection Pressure: When antibiotics are used, they create environmental pressure
  3. Survival of the Fittest: Bacteria with resistance mutations survive while others die
  4. Reproduction: Resistant bacteria multiply and pass resistance genes to offspring
  5. Population Change: Over time, resistant bacteria become dominant in the population

Mechanisms of Resistance:

  • Enzyme Production: Bacteria produce enzymes that break down antibiotics
  • Target Modification: Changes to bacterial structures that antibiotics normally target
  • Efflux Pumps: Bacteria pump antibiotics out of their cells
  • Alternative Pathways: Bacteria develop new metabolic routes to bypass disrupted processes

Superbugs: The Resistance Champions

Examples of Antibiotic-Resistant Bacteria:

  • MRSA: Methicillin-Resistant Staphylococcus Aureus - resistant to methicillin and many other antibiotics
  • VRE: Vancomycin-Resistant Enterococci - resistant to vancomycin, often used as last resort
  • MDR-TB: Multi-Drug-Resistant Tuberculosis - resistant to multiple anti-TB drugs
  • XDR-TB: Extensively Drug-Resistant Tuberculosis - resistant to most available treatments
  • CRE: Carbapenem-Resistant Enterobacteriaceae - resistant to carbapenem antibiotics

Why Superbugs Are Dangerous:

  • Limited treatment options available
  • Higher mortality rates from infections
  • Longer hospital stays and recovery times
  • More expensive treatments required
  • Risk of spreading resistance to other bacteria

Preventing Antibiotic Resistance

Individual Actions:

  • Complete the course: Always finish prescribed antibiotics, even if feeling better
  • Don't share: Never share antibiotics with others
  • Don't save: Don't keep leftover antibiotics for future use
  • Don't pressure doctors: Accept that viral infections don't need antibiotics
  • Practice hygiene: Prevent infections through good hand hygiene

Healthcare Measures:

  • Appropriate prescribing - only when necessary
  • Infection control measures in hospitals
  • Rapid diagnostic tests to identify bacterial vs viral infections
  • Surveillance of resistance patterns
  • Isolation of patients with resistant infections

Agricultural Controls:

  • Reduce antibiotic use in livestock
  • Ban growth-promoting antibiotics in animal feed
  • Improve animal welfare to reduce disease
  • Alternative disease prevention strategies

Global Impact of Antibiotic Resistance

Health Consequences:

  • WHO estimates 700,000 deaths annually from resistant infections
  • Could rise to 10 million deaths per year by 2050
  • Routine medical procedures may become life-threatening
  • Cancer chemotherapy and organ transplants at risk
  • Maternal and infant mortality may increase

Economic Impact:

  • Estimated global cost of $100 trillion by 2050
  • Increased healthcare costs from longer treatments
  • Lost productivity from illness and death
  • Reduced economic growth, especially in developing countries
  • High cost of developing new antibiotics

Particular Impact on Developing Countries:

  • Limited access to newer, more expensive antibiotics
  • Higher burden of infectious diseases
  • Inadequate laboratory facilities for proper diagnosis
  • Over-the-counter availability leading to misuse
  • Poor infection control in healthcare facilities

🔬 How New Drugs Are Tested and Approved

Developing a new antibiotic is a long and tightly regulated process. Before any drug reaches patients, it must pass through a series of staged tests that progressively involve more complex living systems. This staged approach exists because safety failures caught early save lives — and money. The full process typically takes 10–15 years and costs over £1 billion per drug.

Stage 1: Pre-clinical Testing (Before Any Humans Are Involved)

Pre-clinical testing happens entirely outside human subjects. Researchers test the potential drug on:

  • Cells and tissues (in vitro): The drug is applied to living cells or tissue samples in a laboratory dish. This checks basic toxicity — does the drug kill human cells? Does it interfere with normal cell function? This step is relatively cheap and fast.
  • Animals (in vivo): The drug is tested in living organisms (typically mice or rats). This reveals how the drug behaves in a whole living system — how it is absorbed, broken down, and excreted by the body. It also identifies side effects that only appear in living organisms and helps establish a safe dosage range.

A drug must pass all pre-clinical tests before it can proceed to any human trials. Many candidate drugs fail here and never move forward.

Stage 2: Clinical Trials — Three Phases

Clinical trials test the drug in human volunteers and patients. They are divided into three phases, each progressively larger:

Phase Who is involved Main purpose
Phase 1 Small group of healthy volunteers (20–100 people) Safety — identify side effects, find the maximum safe dose the human body can tolerate
Phase 2 Larger group of patients who have the disease (100–300 people) Efficacy — does the drug actually work against the disease? What is the optimum dose?
Phase 3 Thousands of patients across multiple sites Large-scale comparison — compare the new drug against existing treatments or a placebo; build statistical confidence that the effect is real

Double-blind Trial Design

In Phase 3 trials, it is critical to remove bias from the results. This is achieved using a double-blind trial:

  • Half the patients receive the real drug; the other half receive a placebo — a dummy treatment that looks and tastes identical but contains no active ingredient.
  • Neither the patient nor the doctor administering the treatment knows who has received the real drug or the placebo. This is what makes the trial "double-blind" — both sides are unaware.
  • Without this, patients who know they are receiving a real drug may report improvement just because they expect to feel better (the placebo effect). Doctors who know which patients received the real drug may unconsciously interpret their symptoms more favourably.
  • Once all data is collected, the blind is broken and results are analysed.

Peer Review and Regulatory Approval

After clinical trials, results are published and subjected to peer review — independent scientists check the methodology and conclusions. Only once a drug has passed peer-reviewed clinical trials and satisfied regulatory bodies (such as the MHRA in the UK) can it be prescribed to patients.

Why New Antibiotics Are So Hard to Develop

  • Time and cost: 10–15 years and over ÂŁ1 billion per drug
  • Regulatory requirements: Every phase must demonstrate safety and efficacy
  • Limited commercial return: Antibiotics are taken for short courses (unlike drugs for chronic conditions), reducing profit incentive for pharmaceutical companies
  • Rapid resistance: Bacteria may develop resistance to a new antibiotic before it even reaches market

Alternative Approaches Being Researched

  • Bacteriophages: Viruses that specifically infect and kill bacteria
  • Antimicrobial peptides: Natural defence molecules found in living organisms
  • Combination therapies: Using two drugs together to reduce the chance bacteria can develop resistance to both simultaneously

Quick Check: Why are drugs tested on animals before being tested on human volunteers?

Exam Tips: Antibiotics vs Other Treatments

Common Exam Mistakes to Avoid:

  • Don't say: "Antibiotics kill viruses" - they only work on bacteria
  • Don't confuse: Antibiotics with antiseptics or disinfectants
  • Don't forget: Fleming discovered penicillin, not all antibiotics
  • Remember: Resistance is due to natural selection, not bacteria "learning"

Key Comparisons:

Infection Type Treatment Examples Outcome
Bacterial Antibiotics Pneumonia, strep throat Can be cured
Viral Antivirals (limited), rest, symptom relief Cold, flu, COVID-19 Usually self-limiting
Fungal Antifungals Thrush, athlete's foot Can be treated

The Future of Infection Control

As we face the growing threat of antibiotic resistance, scientists and healthcare professionals are working on multiple fronts. From developing rapid diagnostic tests that can distinguish bacterial from viral infections in minutes, to research into bacteriophages (viruses that infect and destroy specific bacteria), the future of medicine is being reimagined. However, the success of these innovations will also depend on global cooperation, responsible prescribing practices, and public education about the appropriate use of antibiotics. The race between human innovation and bacterial evolution continues — and the stakes could not be higher.

How It Works: Natural Selection Driving Antibiotic Resistance

Antibiotic resistance is not something that happens to an individual patient — it happens to bacterial populations through the process of natural selection. Understanding this distinction is essential for the exam and for understanding why resistance is so hard to stop.

In any large bacterial population, there is natural genetic variation — different individuals have slightly different DNA sequences due to random mutations. Most mutations are neutral or harmful, but occasionally a mutation confers an advantage: for example, producing an enzyme that breaks down penicillin, or having a slightly altered ribosome that tetracycline cannot bind to.

Normally, these resistant bacteria are rare and have no advantage over non-resistant bacteria. But when antibiotics are introduced, the environment changes dramatically. Non-resistant bacteria are killed by the antibiotic, removing them from the population. Resistant bacteria survive. With competition removed, the resistant bacteria multiply rapidly by binary fission, passing their resistance genes to all daughter cells. Within hours to days, the population is dominated by resistant bacteria.

This is pure natural selection: variation → selection pressure (antibiotic) → differential survival → reproduction → change in population. The bacteria have not "learned" or "decided" to become resistant. Random mutations that happened to confer resistance were selected for by the antibiotic environment. This is why evolution is said to be directionless but can produce the appearance of purpose — the only direction evolution moves is towards whatever survives and reproduces.

The MRSA story illustrates this perfectly: MRSA (Methicillin-Resistant Staphylococcus aureus) emerged because Staphylococcus bacteria with random mutations conferring methicillin resistance survived hospital antibiotic treatment while non-resistant bacteria died. Overuse of antibiotics accelerates this process — the more often antibiotics are used, the stronger the selection pressure favouring resistance.

Key Definitions

Antibiotic: A chemical substance that kills bacteria (bactericidal) or inhibits their growth (bacteriostatic). Examples include penicillin, amoxicillin, and tetracycline. Antibiotics are ineffective against viruses.
Antibiotic resistance: The ability of a bacterium to survive exposure to an antibiotic that would normally kill it or inhibit its growth. Results from natural selection favouring bacteria with resistance-conferring mutations.
Natural selection: The process by which organisms with advantageous heritable traits survive and reproduce at higher rates than those without, leading to changes in allele frequency in the population over time.
Mutation: A random, spontaneous change in the DNA sequence of an organism. In bacteria, rare mutations can confer antibiotic resistance (e.g., producing an enzyme that destroys the antibiotic).
MRSA (Methicillin-Resistant Staphylococcus aureus): A strain of Staphylococcus bacteria that has developed resistance to methicillin and many other antibiotics. A major cause of difficult-to-treat hospital infections.
Selection pressure: An environmental factor (such as an antibiotic) that affects the survival and reproduction of organisms with different traits, driving natural selection.
Zone of inhibition: A clear area around an antibiotic disc on an agar plate where bacteria cannot grow because the antibiotic has diffused into the agar and killed or inhibited them. Larger zones indicate more effective antibiotics.
Plasmid: A small circular piece of DNA found in bacteria, separate from the main chromosome, that can carry resistance genes. Plasmids can be transferred between bacteria (horizontal gene transfer), spreading resistance rapidly.

Double-blind trial: A clinical trial in which neither the patient nor the doctor knows who receives the real drug or the placebo, eliminating bias from both sides.

Placebo: A dummy treatment that looks and feels identical to the real drug but contains no active ingredient. Used as a control in clinical trials to separate the true effect of the drug from the placebo effect (improvement due to believing you are being treated).
Pre-clinical testing: The stage of drug development that takes place before human trials, including testing on cells and tissues (in vitro) and on animals (in vivo), to check for safety and toxicity.
Clinical trial: A staged series of tests on human volunteers and patients (Phase 1, 2, and 3) carried out to determine the safety and effectiveness of a new drug before it can be approved for use.

Common Misconceptions

Misconception: "The person becomes resistant to antibiotics."

Reality: People do not become resistant to antibiotics — bacteria do. When someone says a treatment "stopped working," it means the bacteria in their body have developed resistance through natural selection. The patient's cells are unaffected. The resistance is in the bacterial population, not in the human patient. This is a critical distinction that appears directly in exam mark schemes.

Misconception: "Bacteria deliberately mutate to become resistant."

Reality: Mutations are random. Bacteria do not "decide" to become resistant in response to antibiotics. Mutations occur continuously and randomly during DNA replication. Most are neutral or harmful. A very small number happen to confer resistance. When antibiotics are present, this random variation is acted upon by natural selection — resistant bacteria survive, non-resistant bacteria die. The antibiotic does not cause the mutation; it selects for bacteria that already had it.

Misconception: "Taking antibiotics for a short time reduces resistance risk."

Reality: The advice to "complete the full course" exists because stopping early leaves behind the most resistant bacteria. At the start of treatment, non-resistant bacteria are killed quickly and symptoms improve. But partially resistant bacteria may survive longer. If the course is stopped early, these partially resistant bacteria remain and reproduce, creating a more resistant population. Completing the full course eliminates even partially resistant bacteria before they can dominate.

Misconception: "Antibiotic resistance only matters in hospitals."

Reality: Resistance is a global problem affecting community infections, agriculture, and food safety. Antibiotic use in livestock farming (to promote growth and prevent disease in crowded conditions) is a major driver of resistance. Resistant bacteria can spread from farms to humans through food, water, and direct contact. International travel spreads resistant strains across countries rapidly. WHO estimates antibiotic resistance could cause 10 million deaths per year by 2050 if not addressed — a larger toll than cancer.

Memory Aids

Natural selection for antibiotic resistance — five steps:

  • 1. Variation — random mutation gives one bacterium resistance
  • 2. Selection pressure — antibiotic introduced, kills non-resistant bacteria
  • 3. Survival — resistant bacterium survives
  • 4. Reproduction — resistant bacterium divides rapidly (binary fission)
  • 5. Population change — population becomes dominated by resistant bacteria

MRSA as the memorable example: MRSA = Methicillin-Resistant Staphylococcus Aureus. "Golden staph" (Staphylococcus aureus) is a common skin bacterium. Overuse of methicillin in hospitals selected for resistant strains. MRSA now requires last-resort antibiotics such as vancomycin. This story illustrates every step of the natural selection mechanism in a real-world hospital context.

Why finishing the course matters — "Kill the last one standing": The bacteria that survive longest on antibiotics are the most resistant. Stopping early when you feel better leaves these most-resistant individuals alive to reproduce. Completing the course kills even the hardiest survivors, preventing a more resistant population from developing.

Penicillin mechanism: Penicillin works by blocking the cross-linking of peptidoglycan chains during bacterial cell wall synthesis. When bacteria divide, they cannot build proper cell walls. The cells burst due to osmotic pressure. This is why penicillin does not affect human cells — we have no cell walls. Resistance often involves a bacterial enzyme (beta-lactamase) that breaks down the penicillin molecule before it can act.

Quick Check: A patient stops taking their antibiotic course after 4 days because they feel better, even though they were prescribed a 7-day course. Explain the potential consequences of this decision in terms of natural selection and antibiotic resistance.

Quick Check: A student argues that we should use antibiotics freely because bacteria will eventually develop resistance anyway, so restricting antibiotic use will not help. Evaluate this argument.

Quick Check: In a disc diffusion experiment, Antibiotic A produces a zone of inhibition with diameter 22mm, and Antibiotic B produces a zone of diameter 8mm. The control disc (water) shows no zone. Interpret these results and explain what they suggest about appropriate treatment for this bacterial strain.

Exam Focus

Very Frequently Examined

Antibiotic resistance is one of the most consistently examined topics across all GCSE Biology specifications. Edexcel 1BI0 Paper 1 (Topic 5: Health, Disease and Medicine) tests this topic with scenario-based questions — you may be given a table of zone of inhibition data or a passage about antibiotic prescribing rates and asked to "Suggest" or "Evaluate." Natural selection mechanism questions and data interpretation questions both appear regularly. Edexcel mark schemes commonly use "Accept…" and "Allow…" for the natural selection steps, so ensure you know all the key steps.

  • Natural selection mechanism (4-5 marks): Random mutation → resistance gene present in a few bacteria → antibiotic kills non-resistant → resistant survive → reproduce → pass on resistance → population dominated by resistant bacteria. Every step is required for full marks. The word "mutation" must appear.
  • Why not use antibiotics for viral infections (2 marks): Antibiotics target bacterial structures (cell walls, ribosomes). Viruses do not have these structures. Therefore antibiotics have no target and are ineffective. Also: unnecessary use accelerates resistance.
  • Disc diffusion practical (3-4 marks): Measure zone of inhibition, compare sizes, link to antibiotic effectiveness. Know variables, know why 25°C is used, know what a control shows.
  • Evaluating measures to reduce resistance (4 marks): Complete antibiotic courses, prescribe only for bacterial infections, reduce agricultural use, develop new antibiotics, better diagnostic tests. For each, explain HOW it reduces resistance (reduces selection pressure, prevents resistant strains surviving, etc.).

Common mark losses: Saying the person becomes resistant (it is the bacteria, not the person). Saying bacteria "learn" to resist (it is random mutation + selection). Not including the word "mutation" in natural selection answers. Forgetting that large zone = more effective (not the other way around).

Exam Tips: Antibiotics and Resistance

The word "mutation" is non-negotiable: Every mark scheme for antibiotic resistance questions includes "mutation" as a required term. Resistance does not arise from "adaptation," "evolution," or "change" alone — it specifically arises from random mutation. Without this word, you will lose marks regardless of how good the rest of your answer is.

Bacteria become resistant, not people: This distinction is explicitly tested. "The patient became resistant to the antibiotic" is wrong and would lose marks. "The bacteria in the patient became resistant" is correct. The antibiotic affected the bacterial population through natural selection; the human patient's physiology is irrelevant to resistance.

Natural selection sequence must be in order: Variation (mutation) → Selection pressure (antibiotic) → Differential survival (resistant survive) → Reproduction → Population change. If you give these steps in the wrong order or skip one, you will lose marks. Practice writing this sequence until it is automatic.

Disc diffusion — big zone means effective: A large zone of inhibition means the antibiotic diffused far from the disc and killed bacteria over a wide area. A small zone means limited effectiveness. No zone on control disc validates the experiment (the disc itself has no effect). Calculate area using pi x r squared for higher marks.

Link reduction strategies to mechanism: Each strategy reduces resistance by reducing selection pressure or slowing spread. "Complete the course" kills even partially resistant bacteria before they can dominate. "Only prescribe for bacterial infections" means fewer bacteria are exposed to antibiotics, so fewer are selected for resistance. Always explain the mechanism, not just state the strategy.

MRSA is the go-to example: MRSA (Methicillin-Resistant Staphylococcus aureus) is the AQA-favourite named example of antibiotic resistance. Mention it in extended answers to demonstrate specific knowledge. A resistant strain that now requires last-resort antibiotics — showing the real-world consequence of resistance evolution.

Make this stick

Signing in gives access to all PrepWise features.

PrepWise is a trading name of A3M Quality Solutions Limited, registered in England and Wales, company number 14959172. Registered office: 202 Stroud Road, Gloucester, GL1 5LA. ICO registration ZC267069.